Compare · EW vs MDT
EW vs MDT
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. EW focuses on Industrial Specialties, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $131.57B, about 2.1x EW ($61.61B).
- Over the past year, EW is up 24.2% and MDT is up 7.3% - EW leads by 16.9 points.
- MDT has been more active in the news (16 items in the past 4 weeks vs 13 for EW).
- Both have 25 recent analyst ratings on file.
- Company
- Edwards Lifesciences Corporation
- Medtronic plc.
- Price
- -
- -
- Market cap
- $61.61B
- $131.57B
- 1M return
- +21.70%
- +7.75%
- 1Y return
- +24.21%
- +7.30%
- Industry
- Industrial Specialties
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 13
- 16
- Recent ratings
- 25
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest EW
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 101 shares, decreasing direct ownership by 0.69% to 14,606 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $64,531 worth of shares (619 units at $104.25) as part of a pre-agreed trading plan (SEC Form 4)
- CEO Zovighian Bernard J exercised 23,100 shares at a strike of $72.68 and sold $2,379,779 worth of shares (23,100 units at $103.02) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr exercised 48,900 shares at a strike of $72.68 and sold $5,039,311 worth of shares (48,900 units at $103.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 22,798 units (SEC Form 4)
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Edwards Lifesciences upgraded by Robert W. Baird with a new price target
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Third Quarter Results
- Edwards Lifesciences upgraded by Truist with a new price target
Latest MDT
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)
- Medtronic to announce financial results for its second quarter of fiscal year 2027
- /C O R R E C T I O N - The Michael J. Fox Foundation for Parkinson's Research/
- Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
- Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain Stimulation